的建立和選擇具有挑戰(zhàn)性。同時(shí)大分子抗體和小分子組分的藥物,生物分析方法的組合對(duì)了解ADC的體外與體內(nèi)過(guò)程,認(rèn)識(shí)藥物運(yùn)送到作用部位和暴露反應(yīng)關(guān)系十分重要。因此,對(duì)ADC的開發(fā)策略、新生物分析方法的開發(fā)、建立和驗(yàn)證,以及臨床前和臨床PK、PK/PD研究的問(wèn)題的挑戰(zhàn)和機(jī)遇必須有足夠認(rèn)識(shí)。就ADC的藥動(dòng)學(xué)研究的進(jìn)展和難點(diǎn)予以介紹,以期與從事該類藥物的研究者一起討論和分析。;Antibody drug conjugate (ADC) therapeutics utilized the specificity of monoclonal antibodies (mAbs) and potency of highly toxic small molecules. ADCs are typically composed of an mAb with a cytotoxin conjugated to it, resulting in a new eterogeneous mixture of mAb with various numbers of toxins. Due to this heterogeneity characterized by the therapeutic drug-to-antibody ratio, the selection of bioanalytical methods used to understand and develop ADCs can be challenging. Since the therapeutic drugs have both large- and small-molecule components, and one can use bioanalytical methods in both spaces. A combination of bioanalytical methods is typically used to understand the ADC in vitro/in vivo, to understand payload delivery to the site of action, and to establish an exposure-response relationship. Therefore, many challenges and opportunities to learn are involved with this approach, including issues related to ADC analysis strategies and application of these methods to ADC development, analytical establishment and validation, preclinical and clinical PK, PK/PD studies. In this paper, we introduced the progress and difficulties on pharmacokinetic studies of the ADC in order to engage researchers to discuss and analyze the issues on ADC pharmacokinetic studies."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁(yè) > 過(guò)刊瀏覽>2014年第37卷第3期 >2014,37(3):193-200. DOI:10.7501/j.issn.1674-6376.2013.03.001
上一篇 | 下一篇

抗體藥物偶聯(lián)物(ADC)藥動(dòng)學(xué)研究的認(rèn)識(shí)

Understanding of pharmacokinetic study of antibody drug conjugates

發(fā)布日期:2014-06-06
您是第位訪問(wèn)者
藥物評(píng)價(jià)研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號(hào) 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號(hào):(津)-非經(jīng)營(yíng)性-2015-0031